modelAlitretinoin
Extends from Pharmacolibrary.Drugs.ATC.L.L01XF02.
Information
| name: | Alitretinoin | |
| ATC code: | L01XF02 | route: | oral |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 14 | L |
| clearance: | 20 | L/h |
| other parameters in model implementation | ||
Alitretinoin (9-cis-retinoic acid) is a retinoid approved for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. It is also under investigation or historical use for AIDS-related Kaposi's sarcoma. Alitretinoin acts on both retinoid X receptors (RXRs) and retinoic acid receptors (RARs), modulating cell growth and differentiation.
Pharmacokinetics
Pharmacokinetic model parameters are based on healthy adults from data compiled in regulatory submissions and review articles. Published PK studies are limited; below values are derived from secondary sources and drug monographs.
References
Napolitano, M, et al., & Patruno, C (2022). Alitretinoin for the treatment of severe chronic eczema of the hands. Expert opinion on pharmacotherapy 23(2) 159–167. DOI:10.1080/14656566.2021.1998457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34789049
Wadler, S, et al., & Haynes, H (1999). Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. The cancer journal from Scientific American 5(3) 165–170. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10367173
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)